Latest Oncology News

FDA Places Partial Clinical Hold on Phase 1 Study of NUV-422 in Solid Tumors

FDA Places Partial Clinical Hold on Phase 1 Study of NUV-422 in Solid Tumors

June 27th 2022

Kristi Rosa

The FDA has placed a partial clinical hold on the phase 1/2 NUV-422-02 trial evaluating the selective small molecule CDK2/4/6 inhibitor NUV-422 in patients with solid tumors such as high-grade glioma, hormone receptor–positive advanced breast cancer, and metastatic castration-resistant prostate cancer.

Olaparib Approaches EU Approval for BRCA+, High-Risk Early Breast Cancer

Olaparib Approaches EU Approval for BRCA+, High-Risk Early Breast Cancer

June 27th 2022

Caroline Seymour

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of olaparib for the adjuvant treatment of patients with germline BRCA-mutated, HER2-negative, high-risk, early breast cancer who have received neoadjuvant or adjuvant chemotherapy.

Leukemia Pioneers Chronicle Career Experiences and Milestones

Leukemia Pioneers Chronicle Career Experiences and Milestones

June 27th 2022

OncLive Staff

Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the unique pitfalls and successes they’ve experienced as female physicians.

Anlotinib/Sintilimab Combo Confers Long-Term OS Benefit in Advanced Cervical Cancer

Anlotinib/Sintilimab Combo Confers Long-Term OS Benefit in Advanced Cervical Cancer

June 27th 2022

Jason Harris

The combination of anlotinib and sintilimab was found to provide a long-term survival benefit to patients with previously treated advanced cervical cancer.

CHMP Supports Approval for Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer

CHMP Supports Approval for Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer

June 27th 2022

Chris Ryan

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of trastuzumab deruxtecan monotherapy for patients with metastatic HER2-positive breast cancer who have received at least 1 prior anti–HER2-based regimen.

Latest Oncology Videos

All Oncology News

Dr. Yee on Treating Patients with Relapsed Disease in Multiple Myeloma

June 19th 2022

Andrew Yee, MD

Andrew Yee, MD, discusses treating patients with relapsed disease in multiple myeloma.

Markman Highlights Key Areas of Investigation in Oncology

June 19th 2022

Maurie Markman, MD

Maurie Markman, MD, offers expert insights on the hurdles facing community oncologists, the uptake of biomarkers in the clinic, and an overview of what to look forward to in his area of expertise: gynecologic oncology.

Maintenance Cabozantinib/Avelumab Combo Under Investigation in Metastatic Urothelial Cancer

June 18th 2022

Ryan Scott

The addition of cabozantinib to avelumab is under exploration as a maintenance approach in patients with metastatic urothelial cancer following first-line, platinum-based chemotherapy.

Elacestrant (Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial

June 17th 2022

Aditya Bardia, MD, MPH

Repotrectinib Receives Breakthrough Therapy Designations in China for ROS1+ NSCLC

June 17th 2022

Chris Ryan

The China National Medical Products Administration’s Center for Drug Evaluation granted 2 breakthrough therapy designations to repotrectinib for the treatment of patients with ROS1-positive metastatic non–small cell lung cancer.

FDA Grants Fast Track Designation to Dianhydrogalactitol for Newly Diagnosed Glioblastoma

June 17th 2022

Chris Ryan

The FDA has granted a fast track designation to dianhydrogalactitol for the treatment of patients with newly-diagnosed unmethylated glioblastoma.

Fedratinib with GI Prophylaxis Has Tolerable Safety Profile in Myelofibrosis After Prior Ruxolitinib

June 17th 2022

Ashling Wahner

Fedratinib was shown to be generally well tolerated in older patients with myelofibrosis who had received at least 3 months of prior ruxolitinib, according to findings from the phase 3b FREEDOM trial.

Individualized Care Informs Treatment Modality Choices in Pelvic and Sacral Ewing Carcinoma

June 17th 2022

Ashling Wahner

R. Lor Randall, MD, FACS, discusses the similar benefits offered by radiation and surgery, improved surgical techniques, concerns with morbidity with each approach, and the next steps surgeons and radiation therapists can take to increase patient survival in nonmetastatic pelvic and sacral Ewing carcinoma.

Study Finds Wide Variations in Prostate Cancer Risk Within Hispanic Subgroups

June 17th 2022

University of Miami Health System

Research underscores the need to subdivide Hispanics and other racial and ethnic groups to fully understand actual disparities.

FDA Approval Sought for Momelotinib in Myelofibrosis

June 17th 2022

Kristi Rosa

A new drug application seeking the approval of momelotinib for the treatment of patients with myelofibrosis has been submitted to the FDA.

Radiation Segmentectomy for Curative Intent of Unresectable HCC (RASER): A Prospective, Single Arm Study

June 17th 2022

Edward Kim, MD, Mount Sinai Medical Center

Dr. Kim reviews the RASER study and discusses how radiation segmentectomy could be a potential treatment option for patients with unresectable hepatocellular carcinoma.

Adjuvant and Neoadjuvant Treatments Chart New Course in Advanced RCC

June 17th 2022

Brittany Lovely

A panel of kidney cancer experts discuss how therapeutic strategies in the neoadjuvant and adjuvant settings are affecting outcomes and how treatment selection in the first line has shifted approaches in the second and later lines of therapy.

RARA Gene Expression in Higher-Risk MDS

June 17th 2022

Gustavo Rivero, MD

Dr Gustavo Rivero talks about the significance of the RARA gene in patients with higher-risk MDS.

Biomarker Testing in AML

June 17th 2022

Daniel Pollyea, MD, MS

Dr Daniel Pollyea comments on biomarker testing in acute myeloid leukemia and the potential role for RARA testing.

Overview of Myelodysplastic Syndrome and the Importance of Biomarker Testing

June 17th 2022

Gustavo Rivero, MD

An overview of myelodysplastic syndrome (MDS) and the role of biomarker testing in patients with the disorder.

See All News